Revesz L - Search Results

1

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.

Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G. Revesz L, et al. Bioorg Med Chem Lett. 2006 Jan 15;16(2):262-6. doi: 10.1016/j.bmcl.2005.10.015. Epub 2005 Oct 24. Bioorg Med Chem Lett. 2006. PMID: 16249085

2

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Revesz L, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Wolf R, Zimmerlin AG. Revesz L, et al. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2109-12. doi: 10.1016/s0960-894x(02)00336-0. Bioorg Med Chem Lett. 2002. PMID: 12127515

3

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G. Revesz L, et al. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3595-9. doi: 10.1016/j.bmcl.2004.03.106. Bioorg Med Chem Lett. 2004. PMID: 15177482

4

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.

Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G. Revesz L, et al. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3601-5. doi: 10.1016/j.bmcl.2004.03.111. Bioorg Med Chem Lett. 2004. PMID: 15177483

5

Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.

Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R, Heng R, Hiestand P, Jachez-Demange B, Loetscher P, Sparrer H, Schlapbach A, Waelchli R. Revesz L, et al. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5160-4. doi: 10.1016/j.bmcl.2005.08.057. Epub 2005 Sep 28. Bioorg Med Chem Lett. 2005. PMID: 16198561

6

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.

Waelchli R, Bollbuck B, Bruns C, Buhl T, Eder J, Feifel R, Hersperger R, Janser P, Revesz L, Zerwes HG, Schlapbach A. Waelchli R, et al. Among authors: revesz l. Bioorg Med Chem Lett. 2006 Jan 1;16(1):108-12. doi: 10.1016/j.bmcl.2005.09.035. Epub 2005 Oct 19. Bioorg Med Chem Lett. 2006. PMID: 16236504

7

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.

Revesz L, Schlapbach A, Aichholz R, Feifel R, Hawtin S, Heng R, Hiestand P, Jahnke W, Koch G, Kroemer M, Möbitz H, Scheufler C, Velcicky J, Huppertz C. Revesz L, et al. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4715-8. doi: 10.1016/j.bmcl.2010.04.024. Epub 2010 Apr 13. Bioorg Med Chem Lett. 2010. PMID: 20594847

8

SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.

Revesz L, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Zimmerlin AG. Revesz L, et al. Bioorg Med Chem Lett. 2000 Jun 5;10(11):1261-4. doi: 10.1016/s0960-894x(00)00200-6. Bioorg Med Chem Lett. 2000. PMID: 10866395

9

Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.

Schlapbach A, Feifel R, Hawtin S, Heng R, Koch G, Moebitz H, Revesz L, Scheufler C, Velcicky J, Waelchli R, Huppertz C. Schlapbach A, et al. Among authors: revesz l. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6142-6. doi: 10.1016/j.bmcl.2008.10.039. Epub 2008 Oct 11. Bioorg Med Chem Lett. 2008. PMID: 18945615

10

Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.

Velcicky J, Feifel R, Hawtin S, Heng R, Huppertz C, Koch G, Kroemer M, Moebitz H, Revesz L, Scheufler C, Schlapbach A. Velcicky J, et al. Among authors: revesz l. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1293-7. doi: 10.1016/j.bmcl.2009.10.138. Epub 2009 Nov 3. Bioorg Med Chem Lett. 2010. PMID: 20060294

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters